We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$213M
Cap. Flow
-$89.6M
Cap. Flow %
-7.9%
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
32
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$43.3M
2
TERN
Terns Pharmaceuticals
TERN
+$30M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$23.4M
4
TXG icon
10x Genomics
TXG
+$18.8M
5
ELVN icon
Enliven Therapeutics
ELVN
+$16.2M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$44.7M
2
UTHR icon
United Therapeutics
UTHR
+$31.3M
3
HCA icon
HCA Healthcare
HCA
+$17.2M
4
BIIB icon
Biogen
BIIB
+$15.7M
5
WGS icon
GeneDx Holdings
WGS
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Consumer Staples 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JANX icon
76
Janux Therapeutics
JANX
$975M
$2.32M 0.21%
55,500
-102,300
-65% -$4.8M
FDMT icon
77
4D Molecular Therapeutics
FDMT
$544M
$2.28M 0.2%
108,598
-88,500
-45% -$2.22M
WGS icon
78
GeneDx Holdings
WGS
$2.11B
$2.27M 0.2%
87,000
-696,376
-89% -$13.2M
CRVO icon
79
CervoMed
CRVO
$26.3M
$2.17M 0.19%
126,614
– –
RCEL icon
80
Avita Medical
RCEL
$138M
$2.11M 0.19%
267,000
+192,000
+256% +$1.83M
NVCR icon
81
NovoCure
NVCR
$1.87B
$1.87M 0.16%
108,900
-586,859
-84% -$10.3M
INBX icon
82
Inhibrx
INBX
$1.25B
$1.25M 0.11%
+88,470
New +$1.38M
ORIC icon
83
Oric Pharmaceuticals
ORIC
$1.36B
$1.15M 0.1%
163,000
-258,000
-61% -$2.31M
ADVM
84
DELISTED
Adverum Biotechnologies
ADVM
$1.01M 0.09%
+147,246
New +$1.37M
ESTA icon
85
Establishment Labs
ESTA
$2.75B
$682K 0.06%
+15,000
New +$761K
OFIX icon
86
Orthofix Medical
OFIX
$425M
$676K 0.06%
+51,000
New +$699K
MDXG icon
87
MiMedx Group
MDXG
$612M
$574K 0.05%
+82,884
New +$583K
WHWK
88
Whitehawk Therapeutics
WHWK
$207M
$487K 0.04%
+333,227
New +$618K
BCYC
89
Bicycle Therapeutics
BCYC
$276M
$476K 0.04%
23,500
-129,500
-85% -$2.93M
NTRA icon
90
Natera
NTRA
$39.4B
$390K 0.03%
3,600
-83,400
-96% -$8.47M
IOBT
91
DELISTED
IO Biotech
IOBT
$225K 0.02%
+192,670
New +$269K
XERS icon
92
Xeris Biopharma Holdings
XERS
$1.41B
$140K 0.01%
62,083
– –
ANNX icon
93
Annexon
ANNX
$886M
– –
-292,400
Closed -$2.1M
APGE icon
94
Apogee Therapeutics
APGE
$10.1B
– –
-20,000
Closed -$1.33M
ARQT icon
95
Arcutis Biotherapeutics
ARQT
$3.38B
– –
-225,000
Closed -$2.23M
BIIB icon
96
Biogen
BIIB
$30.8B
– –
-72,800
Closed -$15.7M
CMPS
97
Compass Pathways
CMPS
$1.82B
– –
-565,550
Closed -$4.71M
DNLI icon
98
Denali Therapeutics
DNLI
$3.85B
– –
-47,000
Closed -$964K
DNTH icon
99
Dianthus Therapeutics
DNTH
$6.07B
– –
-100,000
Closed -$3M
FOLD
100
DELISTED
Amicus Therapeutics
FOLD
– –
-57,966
Closed -$683K
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Soleus Capital Management held 116 positions worth $1.13B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Soleus Capital Management withdrew a net $89.6M in Q2 2024, closing 24 positions and reducing 25 holdings. Its most notable exit was HCA Healthcare, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Terns Pharmaceuticals worth $33.7M.

  • Soleus Capital Management's largest Q2 2024 buy was Terns Pharmaceuticals: 4,947,738 shares worth $33.7M.
  • Soleus Capital Management added most to Iovance Biotherapeutics in Q2 2024, an estimated $43.3M increase.
  • Soleus Capital Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $44.7M.
  • Soleus Capital Management fully exited HCA Healthcare in Q2 2024, selling an estimated $17.2M.
  • Soleus Capital Management's ten largest holdings make up 37% of its $1.13B portfolio in Q2 2024.
  • Soleus Capital Management opened 25 new positions and closed 24 in Q2 2024.
  • Soleus Capital Management's portfolio value fell 16% quarter-over-quarter to $1.13B.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.